Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $692,080.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the sale, the chief financial officer now owns 109,491 shares in the company, valued at $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Andrew Guggenhime also recently made the following trade(s):

• On Wednesday, December 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX opened at $89.64 on Friday. The stock has a 50 day moving average price of $87.24 and a 200 day moving average price of $93.85. The stock has a market capitalization of $11.17 billion, a PE ratio of -19.49 and a beta of 0.98. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.27. During the same period last year, the company posted ($0.91) earnings per share. As a group, research analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Institutional Trading of Vaxcyte

A number of large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in shares of Vaxcyte by 23.1% in the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock valued at $1,247,954,000 after purchasing an additional 2,052,989 shares during the period. RA Capital Management L.P. raised its stake in Vaxcyte by 5.9% in the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock valued at $992,914,000 after buying an additional 485,436 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Vaxcyte by 47.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company’s stock valued at $148,075,000 after buying an additional 419,600 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Vaxcyte during the 3rd quarter worth approximately $41,114,000. Finally, Maverick Capital Ltd. increased its holdings in shares of Vaxcyte by 93.7% during the 2nd quarter. Maverick Capital Ltd. now owns 687,908 shares of the company’s stock worth $51,944,000 after acquiring an additional 332,777 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analysts Set New Price Targets

PCVX has been the topic of several research reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $145.71.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.